Ascelia Pharma AB (ACE) AI Stock Analysis

• Market Cap: €390.59M
• Dividend Yield: N/A
• Average Volume (3M): 1.75M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: N/A
• EPS Growth: 31.62%
• Country: SE
• Employees: 11
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.13
• Shares Outstanding: 126,815,460
• 10 Day Avg. Volume: 1,883,755
• 30 Day Avg. Volume: 1,753,338
• PEG Ratio: 0.04
• Price to Book (P/B): 2.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: ―

Ascelia Pharma AB's overall stock score reflects significant financial challenges due to zero revenue and consistent net losses, offset slightly by a strong cash position. Technical analysis indicates positive momentum, but the speculative nature of the stock, highlighted by a negative P/E ratio and lack of profitability, results in a low overall score. The stock remains highly speculative, hinging on future product development success.

Ascelia Pharma AB Business Overview & Revenue Model

Company Description

Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.

How the Company Makes Money

Ascelia Pharma AB generates revenue primarily through the research and development of its proprietary drug candidates. The company aims to monetize its products by progressing them through clinical trials and eventually bringing them to the market upon regulatory approval. Key revenue streams include potential licensing agreements, partnerships with larger pharmaceutical companies, and eventual sales of approved products. Additionally, Ascelia may receive milestone payments and royalties from collaborations with other entities in the pharmaceutical industry. The company's success in securing partnerships and advancing its drug candidates through the development pipeline is crucial to its financial performance.

Ascelia Pharma AB Financial Statement Overview

Summary

Ascelia Pharma AB exhibits a challenging financial position typical of early-stage biotech companies. The absence of revenue and persistent net losses, combined with a reliance on external financing, underscore the financial risks associated with the company's operations. However, a strong cash position offers some buffer against immediate liquidity concerns, though long-term sustainability hinges on successful product development and commercialization.

Income Statement

Ascelia Pharma AB has struggled to generate revenue over the past several years, with total revenue consistently at zero. Despite efforts to control costs, the company has reported significant net losses each year, indicative of its heavy R&D expenditure typical within the biotechnology industry. The absence of revenue and consistent negative net income results in extremely poor margins, reflecting a challenging financial position.

Balance Sheet

The balance sheet shows a moderately healthy equity position with a strong level of cash and cash equivalents. However, the company's debt-to-equity ratio has increased over time, reflecting a growing reliance on debt financing. The equity ratio remains stable but has slightly declined, indicating a gradual erosion of equity relative to assets.

Cash Flow

The company's operating cash flow is persistently negative, indicating significant cash burn which is common for biotech firms in development stages. Despite this, recent financing activities have provided substantial cash inflows, helping to offset the negative free cash flow. However, sustainable cash flow from operations remains a critical challenge.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-938.00K	-1.05M	-3.89M	-8.72M	-825.00K
EBITDA	-77.13M	-67.69M	-108.56M	-132.06M	-128.42M	-98.91M
Net Income	-88.72M	-80.03M	-109.29M	-131.22M	-125.90M	-98.70M
Balance Sheet
Total Assets	136.41M	140.92M	87.07M	218.57M	333.49M	255.37M
Cash, Cash Equivalents and Short-Term Investments	72.28M	75.26M	21.86M	149.56M	261.60M	184.69M
Total Debt	1.18M	25.40M	1.06M	484.00K	1.66M	1.78M
Total Liabilities	22.01M	61.98M	12.74M	37.71M	25.66M	19.32M
Stockholders Equity	114.40M	78.94M	74.33M	180.86M	307.83M	236.06M
Cash Flow
Free Cash Flow	-52.50M	-62.84M	-126.79M	-125.33M	-116.60M	-85.92M
Operating Cash Flow	-52.45M	-62.84M	-126.79M	-125.26M	-116.56M	-85.53M
Investing Cash Flow	-57.00K	0.00	46.00K	-65.00K	-38.00K	75.99M
Financing Cash Flow	46.86M	115.19M	-936.00K	-1.10K	184.87M	92.72M

Ascelia Pharma AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACE, the sentiment is Negative. The current price of 2.65 is below the 20-day moving average (MA) of 2.93, below the 50-day MA of 3.10, and below the 200-day MA of 3.71, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 28.84 is Positive, neither overbought nor oversold. The STOCH value of 8.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACE.

Ascelia Pharma AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XBRANE	48 Neutral	€217.39M	1.17	-16.90%	―	4.64%	―
IMMU	47 Neutral	€276.05M	―	-16.51%	―	―	31.37%
ACE	43 Neutral	€390.59M	-2.68	-79.60%	―	―	31.62%
ISOFOL	36 Underperform	€202.40M	―	-51.35%	―	―	-34.02%
GUARD	32 Underperform	€28.23M	-0.16	-199.25%	―	―	0.30%
CANTA	31 Underperform	€815.45M	-4.15	81.19%	―	―	―